Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT06927024
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Active taVNS — DEVICE
    Active taVNS delivered via the TENS Device 7000.
  • Sham taVNS — DEVICE
    Sham taVNS delivered via the TENS Device 7000.

Study Details

30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.

Key Dates

Start date
Oct 15, 2025
Status verified
Apr 2025
Primary completion
Jan 31, 2029
Completion
Jan 31, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Active taVNS
    Participants receive two weeks of 15-minute taVNS daily in the morning.
  • Sham Comparator: Sham taVNS
    Participants receive two weeks of 15-minute sham intervention daily in the morning.

Primary Outcome Measure

Proportion of Patients who Complete 2 Weeks of Intervention [ Time Frame: Week 2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016
Qandeel Soomro, MD
[email protected]
212-263-7300

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY

Related Studies